MedTrace Logo

Decitabine in Treating Patients With Advanced Solid Tumors

NCT00030615 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-02-07

No results posted yet for this study

Summary

This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Conditions

  • Male Breast Cancer
  • Recurrent Bladder Cancer
  • Recurrent Breast Cancer
  • Recurrent Melanoma
  • Stage III Melanoma
  • Stage IV Bladder Cancer
  • Stage IV Breast Cancer
  • Stage IV Melanoma
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

decitabine

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Jeffrey Weber · University of Southern California

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030615 on ClinicalTrials.gov